NASDAQ$TWST
Twist Bioscience Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported record revenue and order growth, improved gross margin, and maintained focus on path to profitability.
Twist Bioscience reported a strong second quarter with revenue increasing to $75.3 million, a 25% increase year-over-year, and orders increasing to $93.2 million, a 45% increase year-over-year. The company's gross margin improved to 41%, and they are focused on achieving profitability.
- Total revenue increased to $75.3 million, up 25% compared to the same period last year.
- Total orders increased to $93.2 million, up 45% compared to the same period last year.
- Gross margin improved to 41% compared to 31% for the same period last year.
- Net loss attributable to common stockholders was $45.5 million, or $0.79 per share, compared to $59.2 million, or $1.04 per share, for the same period last year.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$75.3M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience updated its financial guidance for fiscal year 2024 and provided guidance for the third and fourth quarters of fiscal year 2024.
Tailwinds
- Total revenue is expected to be in the range of $300 million to $304 million.
- SynBio revenue is expected to be in the range of $118 million to $120 million.
- NGS revenue is expected to be in the range of $162 million to $164 million.
- Gross margin is expected to be approximately 41.5% to 42.0% for fiscal 2024.
- Ending cash, cash equivalents and short-term investments at September 30, 2024 of more than $245 million.
Headwinds
- Biopharma revenue is expected to be approximately $20 million.
- Loss from operations before taxes of approximately $183 million to $188 million.
- Total revenue for Q3 is expected to be approximately $77 million.
- SynBio revenue for Q3 is expected to be approximately $31 million.
- NGS revenue for Q3 is expected to be approximately $41 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro